Relationships between DNA strand breakage and apoptotic progression upon treatment of HL-60 leukemia cells with tafluposide or etoposide

Anti-Cancer Drugs

Volumn 17, Issue 2, 2006, Pages 155-164

  Kluza, Jérôme ^a   Mazinghien, Romain ^a   Irwin, Helen ^b   Hartley, John A ^b   Bailly, Christian ^c  

^a Institut de Recherche sur le Cancer de Lille   (France)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c INSTITUT DE RECHERCHE PIERRE FABRE   (France)

Author keywords

Apoptosis; Comet assay; DNA strand break; Etoposide; Mitochondria; Reactive oxygen species; Tafluposide; Topoisomerase

Indexed keywords

4',6 DIAMIDINO 2 PHENYLINDOLE; ANTINEOPLASTIC AGENT; DIMETHYL SULFOXIDE; DNA; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); EPIPODOPHYLLOTOXIN DERIVATIVE; ETOPOSIDE; F 11782; REACTIVE OXYGEN METABOLITE; TAFLUPOSIDE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL STRAIN HL 60; COMET ASSAY; CONTROLLED STUDY; CYTOFLUOROMETRY; DEPOLARIZATION; DISEASE COURSE; DNA DAMAGE; DNA STRAND BREAKAGE; HUMAN; HUMAN CELL; HYPERPOLARIZATION; MEMBRANE POTENTIAL; MITOCHONDRION; PRIORITY JOURNAL; PROMYELOCYTIC LEUKEMIA;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; DNA TOPOISOMERASES, TYPE I; DNA TOPOISOMERASES, TYPE II; DNA, NEOPLASM; ETOPOSIDE; HL-60 CELLS; HUMANS; NAPHTHALENES; PYRANS;

EID: 33646259246     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200602000-00006     Document Type: Article

References (28)

1. Perrin D, van Hille B, Barret JM, Kruczynski A, Etievant C, Imbert T, et al. F 11782, a novel epipodophylloid non-intercalating dual catalytic inhibitor of topoisomerases I and II with an original mechanism of action. Biochem Pharmacol 2000; 59:807-819.
2. Barret JM, Hill BT, Olive PL. Characterization of DNA-strand breakage induced in V79 cells by F 11782, a catalytic inhibitor of topoisomerases. Br J Cancer 2000; 83:1740-1746.
3. Barret JM, Montaudon D, Etievant C, Perrin D, Kruczynski A, Robert J, et al. Detection of DNA-strand breaks in cells treated with F 11782, a catalytic inhibitor of topoisomerases I and II. Anticancer Res 2000; 20:4557-4562.
4. Barret JM, Kruczynski A, Etievant C, Hill BT. Synergistic effects of F 11782, a novel dual inhibitor of topoisomerases I and II, in combination with other anticancer agents. Cancer Chemother Pharmacol 2002; 49:479-486.
5. Barret JM, Cadou M, Hill BT. Inhibition of nucleotide excision repair and sensitization of cells to DNA cross-linking anticancer drugs by F 11782, a novel fluorinated epipodophylloid. Biochem Pharmacol 2002; 63:251-258.
6. Barret JM, Etievant C, Baudouin C, Skov K, Charveron M, Hill BT. F 11782, a novel catalytic inhibitor of topoisomerases I and II, induces atypical, yet cytotoxic DNA double-strand breaks in CHO-K1 cells. Anticancer Res 2002; 22:187-192.
7. Kruczynski A, Barret JM, van Hille B, Chansard N, Astruc J, Menon Y, et al. Decreased nucleotide excision repair activity and alterations of topoisomerase IIalpha are associated with the in vivo resistance of a P388 leukemia subline to F11782, a novel catalytic inhibitor of topoisomerases I and II. Clin Cancer Res 2004; 10:3156-3168.
8. Jensen LH, Renodon-Corniere A, Nitiss KC, Hill BT, Nitiss JL, Jensen PB, et al. A dual mechanism of action of the anticancer agent F 11782 on human topoisomerase II alpha. Biochem Pharmacol 2003; 66:623-631.
9. Kingma PS, Burden DA, Osheroff N. Binding of etoposide to topoisomerase II in the absence of DNA: decreased affinity as a mechanism of drug resistance. Biochemistry 1999; 38:3457-3461.
10. Baldwin EL, Osheroff N. Etoposide, topoisomerase II and cancer. Curr Med Chem Anticancer Agents 2005; 5:363-372.
11. Etievant C, Kruczynski A, Barret JM, Perrin D, van Hille B, Guminski Y, et al. F 11782, a dual inhibitor of topoisomerases I and II with an original mechanism of action in vitro, and markedly superior in vivo antitumour activity, relative to three other dual topoisomerase inhibitors, intoplicin, aclarubicin and TAS-103. Cancer Chemother Pharmacol 2000; 46:101-113.
12. Kruczynski A, Etievant C, Perrin D, Imbert T, Colpaert F, Hill BT. Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases. Br J Cancer 2000; 83:1516-1524.
13. Kruczynski A, Ricome C, Waud WR, Hill BT. In vivo antitumor activity of F 11782, a non-intercalating dual catalytic inhibitor of topoisomerases I and II, against a panel of human tumor xenografts. J Exp Ther Oncol 2002; 2:219-227.
14. Van Hille B, Etievant C, Barret JM, Kruczynski A, Hill BT. Characterization of the biological and biochemical activities of F 11782 and the bisdioxopiperazines, ICRF-187 and ICRF-193, two types of topoisomerase II catalytic inhibitors with distinctive mechanisms of action. Anticancer Drugs 2000; 11:829-841.
15. Etievant C, Kruczynski A, Barret JM, Perrin D, Hill BT. Apoptotic cell death induction by F 11782 a novel dual catalytic inhibitor of topoisomerases I and II. Biochem Pharmacol 2003; 65:755-763.
16. Kluza J, Marchetti P, Gallego MA, Lancel S, Fournier C, Loyens A, et al. Mitochondrial proliferation during apoptosis induced by anticancer agents: effects of doxorubicin and mitoxantrone on cancer and cardiac cells. Oncogene 2004; 23:7018-7030.
17. Salvioli S, Ardizzoni A, Franceschi C, Cossarizza A. JC-1, but not DiOC6(3) or rhodamine 123, is a reliable fluorescent probe to assess delta psi changes in intact cells: implications for studies on mitochondrial functionality during apoptosis. FEBS Lett 1997; 411:77-82.
18. Facompre M, Wattez N, Kluza J, Lansiaux A, Bailly C. Relationship between cell cycle changes and variations of the mitochondrial membrane potential induced by etoposide. Mol Cell Biol Res Commun 2000; 4:37-42.
19. Buckman JF, Hernandez H, Kress GJ, Votyakova TV, Pal S, Reynolds IJ. MitoTracker labeling in primary neuronal and astrocytic cultures: influence of mitochondrial membrane potential and oxidants. J Neurosci Methods 2001; 104:165-176.
20. Guminski Y, Cugnasse S, Fabre V, Monse B, Kruczynski A, Etievant C, et al. Synthesis and antitumor activity of a novel epipodophylloid: F 11782, a dual inhibitor of topoisomerases I and II. Proc Am Ass Cancer Res 1995; 40:4510.
21. Sargent JM, Elgie AW, Williamson CJ, Hill BT. Ex vivo effects of the dual topoisomerase inhibitor tafluposide (F 11782) on cells isolated from fresh tumor samples taken from patients with cancer. Anticancer Drugs 2003; 14:467-473.
22. m) in apoptosis; an update. Apoptosis 2003; 8:115-128.
23. Scarlett JL, Sheard PW, Hughes G, Ledgerwood EC, Ku HH, Murphy MP. Changes in mitochondrial membrane potential during staurosporine-induced apoptosis in Jurkat cells. FEBS Lett 2000; 475:267-272.
24. Sanchez-Alcazar JA, Ault JG, Khodjakov A, Schneider E. Increased mitochondrial cytochrome c levels and mitochondrial hyperpolarization precede camptothecin-induced apoptosis in Jurkat cells. Cell Death Differ 2000; 7:1090-1100.
25. Pham NA, Hedley DW. Respiratory chain-generated oxidative stress following treatment of leukemic blasts with DMA-damaging agents. Exp Cell Res 2001; 264:345-352.
26. Kluza J, Lansiaux A, Wattez N, Mahieu C, Osheroff N, Bailly C. Apoptotic response of HL-60 human leukemia cells to the antitumor drug TAS-103. Cancer Res 2000; 60:4077-4084.
27. Eliseev RA, Gunter KK, Gunter TE. Bcl-2 prevents abnormal mitochondrial proliferation during etoposide-induced apoptosis. Exp Cell Res 2003; 289:275-281.
28. Reipert S, Berry J, Hughes MF, Hickman JA, Allen TD. Changes of mitochondrial mass in the hemopoietic stem cell line FDCP-mix after treatment with etoposide: a correlative study by multiparameter flow cytometry and confocal and electron microscopy. Exp Cell Res 1995; 221:281-288.